BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 20, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
June 6, 2006
View Archived Issues
BG-00012 safe and reduces brain lesions in relapsing-remitting multiple sclerosis
Read More
Gallium maltolate demonstrates effective and safe antibacterial activity in UTI
Read More
Lexicon Genetics and BMS extend neuroscience alliance by two years
Read More
Neuroprotective effects of NNZ-2556 target delayed cell death
Read More
VAS-203 reduces ICP posttraumatic brain injury and improves neurological function
Read More
Dosing completed in phase Ib study of AL-208 for neurodegenerative diseases
Read More
ICES and MerLion enter antitumor research collaboration
Read More
Picoplatin begins phase I/II study in hormone-refractory metastatic prostate cancer
Read More
Vion updates pipeline progress
Read More
Inspire to file for phase II testing of epinastine for seasonal allergic rhinitis
Read More
CytImmune to begin phase I study of CYT-6091 in advanced cancer
Read More
Plans for Yondelis filings
Read More
Stressgen Biotechnologies changes name to Nventa Biopharmaceuticals
Read More
Large outcomes trial planned for Natrecor
Read More
Phase III study of glufosfamide recommended to continue to completion
Read More
Delay to initiation of phase IIa study of MEM-3454 in Alzheimer's disease
Read More
Target enrollment completed in phase IIa study of E1-I.N.T. in type 1 diabetes
Read More
Life Science Pharmaceuticals acquires three monoclonal antibody programs
Read More
Thelin recommended for approval in Europe
Read More
New therapeutic agents for ocular disorders disclosed
Read More
Novel treatments for inflammatory disorders reported in recent patents
Read More
Patents claim novel therapeutic agents for respiratory disorders
Read More
Preliminary phase I/II results suggest MB-07133 warrants further evaluation in HCC
Read More
Different administration schedules tested for ZK-304709, an oral multitarget tumor growth inhibitor
Read More
Favorable safety, pharmacokinetic and efficacy findings reported for Coramsine
Read More
Safety and maximum tolerated dose of imidacrine defined in phase I trials
Read More
Phase I/II study reveals good efficacy and safety for TG-1042 in CTCL and CBCL
Read More
Intravesical fusion protein associated with excellent tolerability and activity in bladder cancer
Read More
New compounds for the treatment of psychiatric disorders reported
Read More